Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rifaximin Effective for Uncomplicated Diverticulitis in Real-Life Study

Key clinical point: “Real-life” data show a benefit of rifaximin on symptoms and complications experienced by patients with symptomatic uncomplicated diverticular disease of the colon.

Major finding: Acute diverticulitis occurred in 9 patients in the rifaximin group (2.6%) and in 21 patients who did not receive rifaximin (4.5%), a difference that reached statistical significance (P = .155).

Study details: A retrospective study of 816 patients with symptomatic uncomplicated diverticular disease.

Disclosures: The researchers reported having no financial disclosures.

Citation:

REPORTING FROM DDW 2019